比较卡巴他赛与每周紫杉醇用于可手术三阴性或Luminal B/HER2阴性乳腺癌新辅助治疗的疗效与安全性的随机、开放标签、II期研究(GENEVIEVE)
GENEVIEVE是一项前瞻性、多中心、随机、开放标签II期研究,比较卡巴他赛与紫杉醇新辅助治疗可手术HER2阴性乳腺癌的pCR率。333例患者随机分组,卡巴他赛组pCR率1.2%显著低于紫杉醇组10.8%(p=0.001),且严重不良事件更多(25.3% vs 10.2%,p<0.001)。
要点
- 卡巴他赛组pCR率1.2%,显著低于紫杉醇组10.8%(p=0.001)
- 卡巴他赛组严重不良事件25.3%,高于紫杉醇组10.2%(p<0.001)
- 两组剂量减少率无显著差异(9.6% vs 11.4%,p=0.721)
核心结论
- GENEVIEVE研究显示卡巴他赛在三阴性或Luminal B/HER2阴性原发乳腺癌中无短期疗效,两组药物暴露和患者依从性似乎无差异。
研究设计与样本
- 前瞻性、多中心、随机、开放标签II期研究,比较卡巴他赛与紫杉醇新辅助治疗的疗效与安全性。
- 共333例患者随机并开始治疗,卡巴他赛组74.7%、紫杉醇组83.2%完成治疗。
- 卡巴他赛为4个3周周期,紫杉醇为12周方案。
- 主要终点为紫杉烷治疗后乳腺组织学检查无浸润性癌(ypT0/is,ypN0/+)的pCR率。
- 患者此后可接受蒽环类药物治疗。
主要发现
- 卡巴他赛组pCR率1.2%,显著低于紫杉醇组10.8%(p=0.001)。
- 卡巴他赛组42例(25.3%)、紫杉醇组17例(10.2%)发生至少一次严重不良事件(p<0.001)。
- 卡巴他赛组剂量减少9.6%,紫杉醇组11.4%(p=0.721)。
- 剂量减少主因非血液学毒性,卡巴他赛组3.0% vs 紫杉醇组7.8%(p=0.087)。
关键数值与推荐
- pCR定义:紫杉烷治疗后乳腺组织学检查无浸润性癌,不论淋巴结受累(ypT0/is,ypN0/+)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The GENEVIEVE study compared the pathological complete response (pCR) rate (ypT0/is ypN0/+) in patients with operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) treated with either cabazitaxel or paclitaxel. METHODS: GENEVIEVE was a prospective, multicentre, randomised, open-label, phase II study comparing the efficacy and the safety of four 3-weekly cycles cabazitaxel versus 12 weeks of paclitaxel given as neoadjuvant treatment. Primary end-point was the pCR rate defined as the complete absence of invasive carcinoma on histological examination of the breast irrespective of lymph node involvement (ypT0/is, ypN0/+) after the taxane treatment. Patients could receive an anthracycline-based therapy thereafter. RESULTS: Overall, 333 patients were randomised and started treatment with 74.7% and 83.2% of patients completing treatment in the cabazitaxel and paclitaxel arms, respectively. Patients in cabazitaxel arm had a significantly lower pCR rate compared to the paclitaxel arm (1.2% versus 10.8%; p = 0.001). A total of 42 (25.3%) patients in the cabazitaxel arm and 17 (10.2%) in the paclitaxel arm had at least one serious adverse event (p < 0.001). Dose reductions were observed in 9.6% patients in the cabazitaxel arm compared to 11.4% in the paclitaxel arm (p = 0.721). Main reason for dose reductions was non-haematological toxicities in 3.0% versus 7.8% (p = 0.087), respectively. CONCLUSIONS: The GENEVIEVE study showed no short-term effect of cabazitaxel in triple-negative or luminal B/HER2-negative primary BC, while there seemed to be no differences in drug exposure and patient compliance between the two arms. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT01779479.
引用
- Kümmel S, Paepke S, Huober J, et al. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 2017. PMID: 28768217. doi:10.1016/j.ejca.2017.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。